Jitotrimzid 35 Tablet (10 Tab)

Jitotrimzid 35 Tablet Overview:

Jitotrimzid 35 Tablet is an anti-anginal medication primarily used in combination with other medicines to treat angina pectoris (chest pain) caused by coronary artery disease (CAD) in adults.

Jitotrimzid 35 Tablet is prescribed when first-line or single anti-anginal therapy is not sufficient to effectively control the symptoms of angina pectoris.

Angina is a type of chest pain or discomfort that occurs when the heart muscle does not receive enough oxygen-rich blood due to a temporary reduction in blood flow (ischemia).

It contains Trimetazidine Hydrochloride as the active ingredient, which acts as a metabolic modulator to optimize energy utilization within the heart muscle, protecting heart cells from the harmful effects of reduced oxygen supply during ischemic episodes.

Composition:

Each film coated modified release tablet contains- Trimetazidine Hydrochloride: 35 mg and Excipients q.s.

Colour: Iron Oxide Yellow

Uses & Benefits of Jitotrimzid 35 Tablet:

The therapeutic benefits of Jitotrimzid 35 Tablet include:

• Prophylaxis of Angina Pectoris: It is indicated for the long-term symptomatic treatment and prevention of stable angina pectoris (chest pain resulting from decreased oxygen flow to the heart muscle) in adults whose symptoms are inadequately controlled by or who are intolerant to first-line antianginal therapies.
• Myocardial Protection: It enhances the efficiency of oxygen utilization in heart tissues under ischemic conditions, reducing the frequency and severity of sudden chest pain attacks.

How Does Jitotrimzid 35 Tablet Work:

The active ingredient in Jitotrimzid 35 Tablet is Trimetazidine, a piperazine derivative that exerts anti-ischemic properties to manage stable angina pectoris.

During periods of poor blood circulation (ischemia), the heart muscle experiences a drop in oxygen supply. Under normal conditions, heart cells rely heavily on the oxidation of fatty acids for energy, a process that requires a significant amount of oxygen. Trimetazidine works by inhibiting fatty acid oxidation in the mitochondria. Shifting the heart's metabolic energy source from fatty acids to glucose allows the cardiac muscle to generate energy far more efficiently while consuming significantly less oxygen.

Ultimately, this preserves cellular function and prevents tissue damage during ischemic stress—all without directly altering the patient's blood pressure or heart rate.

Dosage of Jitotrimzid 35 Tablet:

• Usage Direction

Take Jitotrimzid 35 Tablet exactly as advised by your doctor, following the prescribed dose and timing. Jitotrimzid 35 Tablet should be swallowed whole with water without breaking, chewing, or crushing it, preferably at the same time each day. Do not stop or alter the dose of Jitotrimzid 35 Tablet without consulting your doctor, as this may prevent you from achieving the desired outcome. If you are unsure about the administration procedures of Jitotrimzid 35, consult with your doctor or pharmacist.

• Missed Dose

If you miss a dose of Jitotrimzid 35 Tablet, take it as soon as you remember on the same day. But, if it is almost time for your next scheduled dose, skip the one you missed and continue following your regular dosing schedule. Avoid taking two doses if you realize you've missed one. If you often frequently forget your medication, consult your doctor to reassess your dosing plan. Missing doses regularly can lead to undesired outcomes.

You can set reminders on your smartphone, keep drug organizer boxes, or use other audio-visual technologies to prevent missing a dose.

• Overdose

If you accidentally take Jitotrimzid 35 Tablet more than your prescribed dose, seek immediate medical advice or go to the nearby poison control centre. An overdose may cause severe adverse events such as dangerously low blood pressure, difficulty breathing, sweating, or loss of consciousness.

Contraindications of Jitotrimzid 35 Tablet:

Do not take Jitotrimzid 35 Tablet if you have a known hypersensitivity or allergy to Trimetazidine or any of the components of this medicine.

It must be avoided in patients with Parkinson’s disease or those presenting with parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders, as the drug can severely aggravate these neurological conditions. Furthermore, the medication is contraindicated for patients suffering from severe renal impairment where the creatinine clearance is less than 30 mL/min.

Additionally, due to a lack of established clinical safety and efficacy data, Jitotrimzid 35 Tablet is not recommended for pediatric patients under 18 years of age.

Precautions & Warnings of Jitotrimzid 35 Tablet:

Before starting Jitotrimzid 35 Tablet, consult your healthcare provider and discuss your complete medical history.

Trimetazidine can potentiate or aggravate parkinsonian symptoms (tremors, stiff posture, slow movements, and unbalanced walk). If any such movement disorders emerge, the medication must be permanently discontinued under medical supervision.

Furthermore, this drug is not indicated as an initial or standalone treatment for unstable angina or acute myocardial infarction. Exercise extreme caution and consider a reduced dosing frequency when treating individuals with moderate renal dysfunction or elderly patients over 75 years of age.

Finally, because Jitotrimzid 35 Tablet functions strictly as a long-term preventive treatment rather than a rescue medication, it must never be relied upon for the immediate relief of a sudden, acute angina attack.

Side Effects of Jitotrimzid 35 Tablet:

While Jitotrimzid 35 Tablet is generally well-tolerated, it may cause side effects, most of which are mild to moderate and typically resolve as the body adjusts to the medication. Commonly reported symptoms include dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, pruritus (itching), rash, and asthenia (weakness). Less common or rare adverse effects include palpitations, tachycardia, sleep disturbances, and orthostatic hypotension, which may cause lightheadedness or falls.

Rare but serious adverse effects include reversible extrapyramidal symptoms—such as tremors, limb rigidity, or involuntary twisting—which gradually subside after drug discontinuation.

Additionally, potential hepatic dysfunction (liver disease), thrombocytopenia (low platelet count), and an increased risk of bruising or bleeding may occur. Patients must seek immediate medical advice if any neurological, hepatic, or severe bleeding symptoms manifest.

Safety Related Concerns of Jitotrimzid 35 Tablet:

• Pregnancy

Jitotrimzid 35 Tablet is usually not recommended during pregnancy, as limited data exist on its safety in pregnant humans. If you are pregnant or planning to become pregnant, talk to your doctor before taking this medication unless the benefits outweigh the risks to the developing baby.

• Breastfeeding

It is recommended to avoid taking Jitotrimzid 35 Tablet while breastfeeding, since it is unknown whether the active ingredient could pass into the breast milk and affect the breastfed child. Therefore, consulting with your doctor before taking Jitotrimzid 35 is crucial.

• Alcohol

Avoid alcohol while taking Jitotrimzid 35 Tablet. Concomitant consumption can compound side effects like dizziness, drowsiness, and altered coordination.

• Food Interactions

It is suggested that the Jitotrimzid 35 Tablet be taken with or without food, but taking it with meals may help mitigate minor gastrointestinal discomfort. To optimize overall therapeutic outcomes, this medication should be paired with a heart-healthy diet, such as one rich in fiber and low in sodium, which helps manage underlying cardiovascular conditions.

To ensure safety, patients with known food allergies or dietary restrictions should consult their healthcare professional before starting the medication.

• Drug Interactions

No severe, clinically distinct drug interactions have been majorly documented for Jitotrimzid 35 Tablet to date. However, to ensure comprehensive therapeutic safety, patients must always share their complete medication history—including prescription drugs, over-the-counter medications, herbal supplements, and other cardiovascular therapies—with their physician prior to starting treatment.

• Using Machinery & Driving

Jitotrimzid 35 Tablet can cause dizziness, drowsiness, or postural instability, which may temporarily impair your coordination. Use caution while driving or operating heavy machinery.

Storage of Jitotrimzid 35 Tablet:

Store below 25°C in a cool and dry place. Protect from light. Keep out of reach of children.

Avoid using it after the expiry date, printed on the packaging. Dispose of expired or unused medication properly; do not throw it away casually.

Additional Information:

• Focus on balanced whole foods rich in dietary fiber, vegetables, and lean proteins, while strictly managing your sodium (salt) intake to control blood pressure.
• Engage in light-to-moderate exercises (like walking) strictly under your cardiologist's guidance to preserve cardiovascular fitness without overexerting the heart muscle.
• Avoid smoking or exposure to secondhand smoke, as nicotine constricts blood vessels and directly undermines the anti-anginal efficacy of your treatment.
• Avoid stopping your medication suddenly unless instructed by your physician.
• Do not share your medicine with someone else having the same symptoms as you.

Frequently Asked Questions (FAQs):

Q: What is Jitotrimzid 35 Tablet used for?

A: Jitotrimzid 35 Tablet is primarily used as an add-on therapy for the long-term, symptomatic management of stable angina pectoris (chronic chest pain) in adults whose symptoms are inadequately controlled by or who are intolerant to first-line antianginal treatments.

Q: Is Jitotrimzid 35 Tablet a beta-blocker?

A: No, it is not a beta-blocker. Unlike beta-blockers, which lower blood pressure and slow down the heart rate, Jitotrimzid 35 Tablet belongs to a class of medications known as metabolic modulators. It works directly at the cellular level to optimize how heart cells utilize oxygen, protecting the heart muscle during ischemic stress without altering your heart rate or blood pressure.

Q: Can I stop taking Jitotrimzid 35 once my chest pain disappears?

A: No, you should not stop taking this medication just because your chest pain has subsided. Jitotrimzid 35 Tablet functions as a long-term preventive treatment designed to maintain cellular energy efficiency in the heart over time. Stopping the medicine abruptly can lead to a recurrence or significant worsening of your angina symptoms. Any changes to your dosage or treatment duration should only be made under the direct supervision and orders of your doctor.

Q: Does Jitotrimzid 35 immediately cure a sudden chest pain attack?

A: No, it will not stop an ongoing acute attack of angina. Jitotrimzid 35 Tablet is designed strictly as a long-term preventive treatment to protect heart cells over time. For immediate relief during an acute chest pain episode, you must use fast-acting rescue medications, exactly as directed by your doctor.

Q: What should I do if I experience shaking or tremors while taking Jitotrimzid 35 Tablet?

A: If you experience hand tremors, muscle stiffness, a slow or unbalanced walk, or any unusual involuntary movements, you should contact your doctor immediately. Jitotrimzid 35 Tablet can occasionally trigger or worsen parkinsonian symptoms. If these movement disorders occur, the medication must be permanently discontinued under proper medical supervision.

Q: Can I take Jitotrimzid 35 Tablet if I have a kidney condition?

A: It depends on the severity of your condition. Jitotrimzid 35 Tablet is strictly contraindicated (must not be taken) if you have severe renal impairment (kidney failure). However, if you have mild-to-moderate kidney dysfunction, your doctor may still prescribe it but will likely adjust your dose to a lower frequency.

References:

1. Trimetazidine 35mg Prolonged-Release Tablets. Trimetazidine dihydrochloride. PACKAGE LEAFLET: INFORMATION FOR THE USER. Last Revised: December 2013. Accessed on: 10th July 2026. Click Here

2. Trimetazidine. Package leaflet. Accessed on: 10th July 2026. Click Here

3. VASTAREL MR. Trimetazidine. Summary of Product Characteristics. Last Revised: March 2021. Accessed on: 10th July 2026. Click Here

4. Feelnor FEM. Trimetazidine Dihydrochloride Tablet. Accessed on: 10th July 2026. Click Here